Literature DB >> 6827921

Antagonism of estrogen action with a new benzothiophene derived antiestrogen.

L J Black, C D Jones, J F Falcone.   

Abstract

A new benzothiophene derived antiestrogen, LY139481, inhibited the uterotropic action of estradiol in a dose related fashion, and at 1 mg per day suppressed more than 90 percent of estradiol's activity in immature rats. LY139481 induced minimal uterotropic activity, and that activity declined in relation to dose. The relative binding affinity of LY139481 for rat uterine cytosol estrogen receptors was greater than that of estradiol in competitive assays and increased in relation to temperature (2.9 +/- 0.5 x estradiol at 30 degrees C). LY139481 caused estradiol-induced uterine hypertrophy to regress in a manner similar to that which resulted from withdrawal of estradiol treatment. Three successive daily injections of LY139481 slightly increased uterine weight, and blocked additional uterotropic action in response to estradiol and LY139481 administration on subsequent days. Furthermore, ten daily injections of estradiol alone did not increase uterine weight in animals pretreated with LY139481 for three days. In contrast, LY139481 did not prevent the partial uterotropic action of tamoxifen administration.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6827921     DOI: 10.1016/0024-3205(83)90935-9

Source DB:  PubMed          Journal:  Life Sci        ISSN: 0024-3205            Impact factor:   5.037


  25 in total

Review 1.  Breast cancer therapies in development. A review of their pharmacology and clinical potential.

Authors:  D de Valeriola; A Awada; J A Roy; A Di Leo; L Biganzoli; M Piccart
Journal:  Drugs       Date:  1997-09       Impact factor: 9.546

2.  Beyond raloxifene for the prevention of osteoporosis and breast cancer.

Authors:  V C Jordan
Journal:  Br J Pharmacol       Date:  2006-11-20       Impact factor: 8.739

3.  The St. Gallen Prize Lecture 2011: evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities.

Authors:  V Craig Jordan; Ifeyinwa Obiorah; Ping Fan; Helen R Kim; Eric Ariazi; Heather Cunliffe; Hiltrud Brauch
Journal:  Breast       Date:  2011-10       Impact factor: 4.380

4.  Structure-function relationships of the raloxifene-estrogen receptor-alpha complex for regulating transforming growth factor-alpha expression in breast cancer cells.

Authors:  Hong Liu; Woo-Chan Park; David J Bentrem; Kevin P McKian; Alexander De Los Reyes; Jessica A Loweth; Jennifer MacGregor Schafer; James W Zapf; V Craig Jordan
Journal:  J Biol Chem       Date:  2001-12-20       Impact factor: 5.157

5.  The influence of antiestrogens on the release of plasminogen activator (uPA) by MDA-MB-231 and MCF-7 breast cancer cells.

Authors:  S M Abidi; E W Howard; J J Dmytryk; J T Pento
Journal:  Clin Exp Metastasis       Date:  1998-04       Impact factor: 5.150

6.  Raloxifene-stimulated experimental breast cancer with the paradoxical actions of estrogen to promote or prevent tumor growth: a unifying concept in anti-hormone resistance.

Authors:  Gregor M Balaburski; Rita C Dardes; Michael Johnson; Bassem Haddad; Fang Zhu; Eric A Ross; Surojeet Sengupta; Andres Klein-Szanto; Hong Liu; Eun Sook Lee; Helen Kim; V Craig Jordan
Journal:  Int J Oncol       Date:  2010-08       Impact factor: 5.650

7.  Proven value of translational research with appropriate animal models to advance breast cancer treatment and save lives: the tamoxifen tale.

Authors:  V Craig Jordan
Journal:  Br J Clin Pharmacol       Date:  2015-02       Impact factor: 4.335

Review 8.  Raloxifene.

Authors:  J A Balfour; K L Goa
Journal:  Drugs Aging       Date:  1998-04       Impact factor: 3.923

9.  Effects of anti-estrogens on bone in castrated and intact female rats.

Authors:  V C Jordan; E Phelps; J U Lindgren
Journal:  Breast Cancer Res Treat       Date:  1987-10       Impact factor: 4.872

10.  A model to describe how a point mutation of the estrogen receptor alters the structure-function relationship of antiestrogens.

Authors:  S Y Jiang; C J Parker; V C Jordan
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.